{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T12:43:40Z","timestamp":1791031420714,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1016\/j.clinthera.2005.10.016","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T12:37:06Z","timestamp":1133786226000},"page":"1588-1595","source":"Crossref","is-referenced-by-count":16,"title":["A randomized, open-label pharmacokinetic comparisonof two oral formulations of fluconazole 150 mg in healthy adult volunteers"],"prefix":"10.1016","volume":"27","author":[{"given":"Du\u0161an","family":"Jovanovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Kilibarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"\u0106iri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slavica","family":"Vu\u010dini\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Srni\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midhad","family":"Vehabovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermina","family":"Potogija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.10.016_bib1","series-title":"Diflucan (fluconazole) [product information]","year":"2005"},{"key":"10.1016\/j.clinthera.2005.10.016_bib2","series-title":"Fluconazole [product information]","year":"2005"},{"key":"10.1016\/j.clinthera.2005.10.016_bib3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2165\/00003088-199324010-00002","article-title":"Clinical pharmacokinetics of fluconazole","volume":"24","author":"Debruyne","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.10.016_bib4","series-title":"Drug Facts and Comparisons","article-title":"Antifungal agents","author":"Olin","year":"2000"},{"key":"10.1016\/j.clinthera.2005.10.016_bib5","series-title":"Clarke's Analysis of Drugs and Poisons","first-page":"1039","article-title":"Fluconazole","year":"2004"},{"key":"10.1016\/j.clinthera.2005.10.016_bib6","first-page":"361","article-title":"Protein binding of itraconazole and fluconazole in patients with chronic renal failure","volume":"32","author":"Arredondo","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.10.016_bib7","series-title":"Bioavailability and Bioequivalence Studies for Orally Administered Drug Products-General Considerations","author":"Guidance for Industry","year":"2003"},{"key":"10.1016\/j.clinthera.2005.10.016_bib8","series-title":"The United States Pharmacopoeia","first-page":"1941","year":"2000"},{"key":"10.1016\/j.clinthera.2005.10.016_bib9","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00007691-199208000-00008","article-title":"Determination of fluconazole in human serum by solid-phase extraction and reversedphase high-performance liquid chromatography","volume":"14","author":"Inagaki","year":"1992","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2005.10.016_bib10","series-title":"Bioanalytical Method Validation","author":"Guidance for Industry","year":"2001"},{"key":"10.1016\/j.clinthera.2005.10.016_bib11","first-page":"293","article-title":"Striving for standards in bioequivalence assessment: A review","volume":"29","author":"Schulz","year":"1991","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"10.1016\/j.clinthera.2005.10.016_bib12","series-title":"Design and Analysis of Bioavailability and Bioequivalence Studies","first-page":"57","year":"2000"},{"key":"10.1016\/j.clinthera.2005.10.016_bib13","series-title":"Statistical Approaches to Establishing Bioequivalence","author":"Guidance for Industry","year":"2001"},{"key":"10.1016\/j.clinthera.2005.10.016_bib14","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5414\/CPP39350","article-title":"Limits of 80%\u2013125% for AUC and 70%\u2013143% for Cmax. What is the impact on bioequivalence studies?","volume":"39","author":"Hauck","year":"2001","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.10.016_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0378-4347(96)00047-3","article-title":"High-performance liquid chromatographic determination of fluconazole in plasma","volume":"686","author":"Cociglio","year":"1996","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.clinthera.2005.10.016_bib16","first-page":"772","article-title":"The comparative bioavailability of a generic and the innovator fluconazole preparations in healthy Thai volunteers","volume":"81","author":"Teekachunhatean","year":"1998","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.clinthera.2005.10.016_bib17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.5414\/CPP38355","article-title":"Pharmacokinetics and bioequivalence testing of generic fluconazole preparations in healthy Thai volunteers","volume":"38","author":"Manorot","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.10.016_bib18","first-page":"752","article-title":"Truncated AUC in the evaluation of fluconazole bioequivalence. A crossover, randomised, open-label study in healthy volunteers","volume":"54","author":"Portoles","year":"2004","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2005.10.016_bib19","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijpharm.2004.09.013","article-title":"Evaluation of the bioequivalence of capsules containing 150 mg of fluconazole","volume":"288","author":"Porta","year":"2005","journal-title":"Int J Pharm"},{"key":"10.1016\/j.clinthera.2005.10.016_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00007691-199904000-00010","article-title":"Fluconazole bioequivalence study: Quantification by tandem mass spectrometry","volume":"21","author":"Moraes","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2005.10.016_bib21","first-page":"1028","article-title":"Comparative bioavailability of two fluconazole capsule formulations in healthy volunteers","volume":"50","author":"Ribeiro","year":"2000","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2005.10.016_bib22","first-page":"39","article-title":"Bioequivalence study of two fluconazole capsule formulations in healthy volunteers","volume":"42","author":"Pereira","year":"2004","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.10.016_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/BF03190263","article-title":"Bioequivalence assessment and the conduct of bioequivalence trials: A European point of view","volume":"21","author":"Herchuelz","year":"1996","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.10.016_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF03190265","article-title":"Bioequivalence assessment of generic drugs: An American point of view","volume":"21","author":"Patnaik","year":"1996","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2005.10.016_bib25","first-page":"391","article-title":"Pharmacokinetics and tolerance of fluconazole suppositories in healthy volunteers","volume":"43","author":"Pfaff","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.clinthera.2005.10.016_bib26","first-page":"282","article-title":"Average bioequivalence of two oral formulations of fluconazole in healthy subjects after multiple dosing","volume":"37","author":"Atanasova","year":"1999","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.10.016_bib27","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/bdd.443","article-title":"Bioequivalence evaluation of two formulations of fluconazole 150 mg capsule in healthy Arab men","volume":"26","author":"Al-Gaai","year":"2005","journal-title":"Biopharm Drug Dispos"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291805002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,20]],"date-time":"2019-01-20T12:51:36Z","timestamp":1547988696000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291805002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["S0149291805002043"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.10.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}